BS Diagnostics

26/02/2026

Le digesteur et les milieux de prélèvement sont actuellement disponibles auprès de

Stream

05/11/2025

We were delighted to participate in AORTIC 2025, held in beautiful Tunisia! 🇹🇳✨

This event was a great opportunity to celebrate the strong partnership between Stilla Technologies and Bio-Rad — a true marriage of innovation and collaboration in the fight against cancer. 💙

A heartfelt thank you to Bio-Rad for their continued support and shared commitment to advancing molecular diagnostics across Africa.

19/10/2025

19/10/2025

11/08/2025

🧬 Multiplex PCR: Target multiple STI pathogens at once!

GeneProof offers a wide selection of real-time PCR kits targeted at STI pathogens. Within our portfolio we offer singleplex, duplex and multiplex assays, and also price-efficient GPacks, for maximum flexibility. Choose your preffered testing strategy for all parameters your lab tests for!

Detect and distinguish most important STI pathogens in a single tube:

🔹 GeneProof CT/NG/MG Multiplex PCR Kit https://www.geneproof.com/geneproof-ct-ng-mg-multiplex-pcr-kit/p1167
🔹 GeneProof MH/UU/UP Multiplex PCR Kit https://www.geneproof.com/geneproof-mh-uu-up-multiplex-pcr-kit/p6676

These assays are CE IVD and IVDR-certified and designed for fast, reliable results in clinical laboratories. With high sensitivity and specificity, they support efficient workflows where multiplexing truly makes a difference.

Explore our product portfolio:
🔗 https://www.geneproof.com/en/products/

Note: Products are intended for in vitro diagnostic use by healthcare professionals only. Please reference the product instructions for use carefully prior to use.

13/07/2025

🩺 Le National Comprehensive Cancer Network ( ) a officiellement mis à jour ses directives, encourageant désormais les cliniciens à discuter des tests pharmacogénétiques DPYD avec les patients subissant une chimiothérapie à base de fluoropyrimidine.

Chez Diatech Pharmacogenetics, nous avons toujours cru que le traitement devrait commencer par l’individu.
C’est pourquoi les tests de font depuis longtemps partie de notre gamme complète et innovante de pharmacogénétique, permettant aux cliniciens d’identifier les patients à risque de toxicité grave et de personnaliser les schémas de chimiothérapie de manière sûre et efficace.

💡 Les variants DPYD peuvent altérer considérablement la capacité d’un patient à métaboliser les fluoropyrimidines, augmentant ainsi le risque d’effets secondaires potentiellement mortels.
Les tests aident à réduire ce risque en guidant des ajustements posologiques ou des traitements alternatifs adaptés au profil génétique de chaque patient.

Nous nous félicitons de cette importante mise à jour et restons déterminés à soutenir l’oncologie de précision grâce à des solutions de pointe qui accordent la priorité à la sécurité des patients et aux résultats.

28/05/2025

Today, on International Women's Health Day 🥰, we honor the strength, resilience, and health of women around the world.

This day serves as a reminder of the importance of prioritizing women's health and well-being in every aspect of life. Join us in spreading awareness and making a difference in women's health! 🍀

14/05/2025

HBV
Characteristics

HIGH SPECIFICITY

• Secured by targeting specific conservative DNA sequence of P gene

• Prevents detection failure caused by the occurrence of mutations (including safe detection of core and pre-core mutants)

• Detection of all HBV genotypes A – H

• 100% diagnostic specificity

HIGH SENSITIVITY

• Ensures excellent sensitivity up to 13.9 IU/ml

• 100% diagnostic sensitivity

W.H.O. STANDARD BASED QUANTIFICATION

• Precise and fully traceable quantification according to 4th WHO International Standard NIBSC 10/266

EASY-TO-USE CONCEPT

• Single tube Ready-to-Use Master Mix contains all components for PCR amplification

• No additional PCR reagents pipetting necessary

CONTAMINATION PREVENTION

• Master Mix contains Uracil-DNA glycosylase (UNG) and dUTPs eliminating carryover contamination

COMPATIBLE WITH A WIDE RANGE OF REAL-TIME PCR DEVICES

06/02/2025

Understanding the role of BRAF mutations in metastatic colorectal cancer (mCRC) can enhance prognostic insights and therapeutic decision making. In this webinar, Michelle Shiller, national medical director of genomics and molecular pathology services at PathGroup, will educate participants on the ep...

04/02/2025

03/02/2025

2ème Journée STGM
Thème : oncogénétique
Date 08 Février 2025